DRG Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s gout forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of gout?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of gout over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following gout subpopulations:

  • Diagnosed 12-month prevalent cases
  • Diagnosed 12-month incident cases
  • Acute gout events per year
  • Lifetime DALYs gained

Note: Coverage may vary by country.

Table of contents

  • Gout - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Prevalence of Gout per 1,000 Among People Aged 20+ in 2019 and 2029
        • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Gout over the Next Ten Years
        • Number of Additional Prevalent Cases of Gout in 2029 in the Countries Under Study due to Trends in Risk or Survival
    • Epidemiology Data
    • Methods
      • Total Prevalence
      • Diagnosed 12-Month Prevalent Cases
      • Acute Gout Events
      • Diagnosed 12-Month Incident Cases
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Gout
        • Studies Excluded from the Analysis of Gout
      • Risk/Protective Factors
        • Risk/Protective Factors for Gout
      • Bibliography

Author(s): Abey John, MPH

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.